全文获取类型
收费全文 | 15559篇 |
免费 | 888篇 |
国内免费 | 480篇 |
专业分类
耳鼻咽喉 | 71篇 |
儿科学 | 489篇 |
妇产科学 | 301篇 |
基础医学 | 1166篇 |
口腔科学 | 121篇 |
临床医学 | 2111篇 |
内科学 | 3003篇 |
皮肤病学 | 77篇 |
神经病学 | 657篇 |
特种医学 | 553篇 |
外科学 | 1549篇 |
综合类 | 2254篇 |
预防医学 | 1698篇 |
眼科学 | 188篇 |
药学 | 1733篇 |
12篇 | |
中国医学 | 555篇 |
肿瘤学 | 389篇 |
出版年
2024年 | 13篇 |
2023年 | 217篇 |
2022年 | 366篇 |
2021年 | 588篇 |
2020年 | 550篇 |
2019年 | 529篇 |
2018年 | 529篇 |
2017年 | 457篇 |
2016年 | 471篇 |
2015年 | 456篇 |
2014年 | 1127篇 |
2013年 | 1365篇 |
2012年 | 883篇 |
2011年 | 1040篇 |
2010年 | 809篇 |
2009年 | 695篇 |
2008年 | 782篇 |
2007年 | 709篇 |
2006年 | 565篇 |
2005年 | 534篇 |
2004年 | 446篇 |
2003年 | 414篇 |
2002年 | 357篇 |
2001年 | 288篇 |
2000年 | 230篇 |
1999年 | 201篇 |
1998年 | 206篇 |
1997年 | 198篇 |
1996年 | 178篇 |
1995年 | 151篇 |
1994年 | 150篇 |
1993年 | 120篇 |
1992年 | 113篇 |
1991年 | 119篇 |
1990年 | 103篇 |
1989年 | 105篇 |
1988年 | 86篇 |
1987年 | 90篇 |
1986年 | 72篇 |
1985年 | 87篇 |
1984年 | 101篇 |
1983年 | 56篇 |
1982年 | 81篇 |
1981年 | 42篇 |
1980年 | 47篇 |
1979年 | 36篇 |
1978年 | 27篇 |
1977年 | 37篇 |
1976年 | 33篇 |
1975年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Zeitschrift für medizinische Physik》2022,32(2):209-217
This work describes a measurement method for assessing dose-related image-quality of CT scans based on the difference detail curve (DDC) method, and showcases its use in a low contrast setting. The method is based on a phantom consisting of elliptical slices of different sizes into which contrast object modules can be inserted. These modules contain contrast objects based on (synthetic) resin mixtures with sucrose (native) or sodium iodine (contrast medium). Mixing ratios are provided to achieve a range of clinically relevant CT-numbers with these materials. The phantom is characterized in terms of contrast accuracy, energy dependency and long-term drift with satisfying results. Contrast accuracy and energy dependency are similar to that of water or soft tissue. Image quality of 655 scans of the phantom acquired at 30 different clinical institutions and with 16 different CT scanner models from 4 manufacturers was assessed by calculating a difference detail curve (DDC) from evaluation of up to 5 human observers using a custom-made software (RadiVates) described in this work. Based on these measurements, inter-observer variability was quantified using a bootstrap method and was shown to be a large contributor to the overall variability. This work demonstrates that assessment of CT image quality is feasible with the aforementioned phantom and DDC method. 相似文献
2.
This meta-analysis was designed to assess the effectiveness and safety of extracorporeal shock wave therapy (ESWT) for patients with low back pain (LBP). Pubmed, Embase, Cochrane's library, PEDro (Physiotherapy Evidence Database), China National Knowledge Infrastructure (CNKI), and Wanfang Data were searched until December 2019 to identify studies assessing the effectiveness and safety of EPSW for LBP. The prime outcome is pain intensity measured by Visual Analog Scale (VAS) or numeric rating scale (NRS). Other outcomes included functional status, quality of life, psychological outcomes measured by Oswestry Disability Index (ODI), as well as the adverse events. Mean differences (MD) were calculated for continuous outcomes, while odd ratios (OR) were calculated for binary outcomes. Revman 5.3 software was used for statistical analysis. Five randomized controlled trials (RCTs) were finally included in this meta-analysis. The pooled mean difference in post-treatment pain scores was −2.37 (P <0.0001), indicating that post-treatment pain scores was significantly higher by 2.37 in control group than in ESWT group. At a mean follow-up time of 4–6 weeks, the pooled mean difference in ODI scores was −14.10 (P <0.00001), indicating that the pooled mean difference of post-treatment ODI scores was 14.10 higher in control group than in ESWT group. The use of ESWT is effective in alleviating pain and improving the general functional state for patients with LBP. However, more evidence was needed to verify its safety. 相似文献
3.
4.
5.
6.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献
7.
目的探讨解偶联蛋白1(UCP1)基因多态性与2型糖尿病(T2DM)心脑血管并发症的相关性。方法选取2019年7月—2020年7月住院治疗的T2DM 440例,根据有无心脑血管并发症分为观察组(T2DM合并心脑血管并发症)221例和对照组(单纯T2DM)219例。比较两组一般资料,UCP1在rs45539933、rs10011540及rs1800592位点的基因型分布与等位基因频率;通过多因素Logistic回归分析评估T2DM发生心脑血管事件的危险因素。结果观察组病程长于对照组,糖化血红蛋白水平高于对照组,而血清高密度脂蛋白胆固醇水平低于对照组(P<0.01)。观察组C/C基因型分布及C碱基频率均高于对照组(P<0.05)。C/C基因型是T2DM患者发生心脑血管并发症的危险因素(P<0.05)。结论UCP1基因多态性与T2DM心脑血管并发症的发生显著相关。 相似文献
8.
目的对玻切二期术后低视力人群采取特殊的护理策略,来平复病人的负面情绪,提高治疗满意度。方法对2019年11月6日至2020年11月6日在我院接受玻璃体切割二次手术的96名低视力患者进行特殊护理干预,然后进行回顾性分析。结果在结合实际病情分析采取的特殊护理策略干预下,病人术后情绪稳定,未出现不良投诉事件,满意度较高。结论对玻切二期术后低视力人群采取特殊的护理干预策略十分必要。 相似文献
9.
10.
随着生活方式的改变,心脑血管疾病逐渐成为全人类死亡的“头号杀手”高于恶性肿瘤、糖尿病等。血脂的升高尤其是低密度脂蛋白胆固醇( LDL-C)的升高与动脉粥样硬化性心血管疾病( ASCVD)的发,生、发展息息相关。现有的专家共识、南提出他汀类药物是降低 LDL-C的一线用药,但仍可能会发生复发性缺血事件。人前蛋白转化酶枯草溶菌素 9(PCSK9)抑制指剂作为一类新型降脂药,有显著降低血 LDL-C水平,同时又可降低脂蛋白( a)的水平,又与 ASCVD与静脉血栓栓塞疾病( VTE)的发病可能相关。本文将系统地阐述新型降脂药 PCSK9抑制剂与 ASCVD、VTE的关系研究进展。 相似文献